Printer Friendly
The Free Library
14,506,614 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Zacks Sell List Highlights: Bally Technologies, Polaris, Millennium Pharmaceuticals and Compuware.


CHICAGO -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Bally bally
Adjective, adv

Brit old-fashioned, slang extreme or extremely: a bally nuisance, he's too bally charming for his own good

Adj. 1.
 Technologies Inc. (NYSE NYSE

See: New York Stock Exchange
: BYI) and Polaris Industries Polaris Industries manufactures a full line of all-terrain vehicles (ATV), snowmobiles, Ranger utility vehicles in 2wd, 4wd or 6wd, Victory Motorcycles and EU rated quadcycles. Polaris no longer manufactures personal water craft or sportboats. Based in Medina, Minnesota.  Inc. (NYSE: PII See Pentium II. ). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Millennium Pharmaceuticals Millennium Pharmaceuticals NASDAQ: MLNM is a biotechnology company based in the Cambridge, Massachusetts area of the United States of America. Founded in 1993, the company conducts research in various scientific areas, currently focusing on inflammation and oncology.  Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: MLNM) and Compuware Corp. (NASDAQ: CPWR CPWR Center to Protect Workers' Rights (now Center for Construction Research and Training)
CPWR Council for a Parliament of the World's Religions
CPWR Coupled Plasma-Waveguide Resonance
). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List Co Stocks to Sell Now by 129.7% annually (11.9% vs. 5.2% respectively). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why BYI and PII have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

Bally Technologies Inc. (NYSE: BYI) has seen next year's earnings estimates drop four cents per share Cents per share

The amount of a mutual fund's dividend or capital gains distributions that a shareholder will receive for each share owned.
 over the past two months. Standard & Poor's Ratings Services downgraded the company after BYI restated revenue and earnings for 2003 to 2005. S&P lowered Bally to a "B-" from "B" and kept the ratings on CreditWatch with negative implications.

Polaris Industries Inc. (NYSE: PII) has experienced a drop in analyst estimates. Earnings estimates for this year stand $2.77 per share, down 32 cents from 60 days ago. The company said that a continued decline in sales of snowmobiles and all-terrain vehicles pushed its third-quarter profit down 12 percent, missing analyst expectations.

Here is a synopsis of why MLNM and CPWR have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks:

Millennium Pharmaceuticals Inc. (NASDAQ: MLNM) has been the target of increasing bearishness bear·ish  
adj.
1. Clumsy, boorish, and surly.

2.
a. Causing, expecting, or characterized by falling stock-market prices.

b.
 by analysts. Over the past three months, next year's estimates have declined 60%. The new consensus estimate calls for two cents per share next year. The company has been involved in a bidding war with Genzyme for AnorMed.

Compuware Corp. (NASDAQ: CPWR) has seen its earnings estimates drop for this year. The current 2006 consensus estimate of 41 cents per share is a penny below the forecast of three months ago. The company said it issued estimates for second-quarter profit and revenue that trail current analyst predictions. Compuware estimated revenue at $288 million, down 3 percent from $296.6 million last year, due to weaker license sales.

Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report; "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions" is available to provide this insightful background. Download a free copy now to prosper in the years to come at http://at.zacks.com/?id=93

About the Zacks Rank

Since 1988, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." A $10,000 investment in the Zacks Rank list made in 1988 would now be worth $1.8 million - equivalent to a 32.4% annualized annualized

Of or relating to a variable that has been mathematically converted to a yearly rate. Inflation and interest rates are generally annualized since it is on this basis that these two variables are ordinarily stated and compared.
 return! During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8%, while the S&P 500 tumbled 37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 145.8% annually (+4.7% vs. +11.6%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.

Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks #1 Rank stocks and highlights those stocks poised to outperform the market. Subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day"
subscribe, take

buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company";
 this free newsletter today by visiting http://at.zacks.com/?id=94

About Zacks

Zacks.com is a property of Zacks Investment Research Zacks Investment Research

A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms.
, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=95

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

(a) The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment Reinvestment

Using dividends, interest and capital gains earned in an investment or mutual fund to purchase additional shares or units, rather than receiving the distributions in cash.

1. In terms of stocks, it is the reinvestment of dividends to purchase additional shares.
 of all dividends, no transaction costs Transaction Costs

Costs incurred when buying or selling securities. These include brokers' commissions and spreads (the difference between the price the dealer paid for a security and the price they can sell it).
, and represents the gross returns before management fees.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 18, 2006
Words:937
Previous Article:ValueSetters Announces New Sourcing Agreement with Faith-Based Marketing Company and Fiscal Years' 2007 and 2008 Revenue Projections.
Next Article:Zacks Buy List Highlights: MICROS Systems, Inc., Harley-Davidson, Inc., CBOT Holdings, Inc. and Safeco Corporation.
Topics:



Related Articles
Zacks Issues Buy Recommendations on the Following 6 Stocks: American Pharma Partners, Garmin, Teva Pharma, BMC Software, Marvel Enterprises, and...
Zacks Issues Buy Recommendations on the Following 6 Stocks: Advance Auto Parts, Micromuse, Zimmer Holdings, Altera, Gilead Sciences and Teva.
Zacks Issues Buy Recommendations on the Following 4 Stocks: Taiwan Semiconductor, Vodafone, Oracle, and Teva Pharmaceutical.
Zacks Sell List Highlights: Shaw Group, TECO Energy, American Capital Strategies, and Compuware.
Zacks Buy List Highlights: Baker Hughes, F5 Networks, Teva Pharmaceutical Industries, and Varian Medical Systems.
Zacks Buy List Highlights: Cummins, Inc., Hilton Hotels Corporation, Cal Dive International, and Compuware Corporation.
Zacks.com Announces That Richard Rhodes Highlights the Following Stocks: Millennium Pharmaceuticals, Johnson & Johnson, Hydril, Input/Output and...
Zacks Analyst Blog Highlights: United Airlines, Pinnacle Airlines, ExpressJet, Frontier Airlines and ACADIA Pharmaceuticals.
Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, United Auto Group and MannKind.
Zacks Analyst Blog Highlights: Millennium Pharmaceuticals, Celgene, Merck and PetMed Express.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles